WT Caiaffa, D Vlahov, NM Graham, J Astemborski, L Solomon, KE Nelson and A Munoz
Department of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205.

To examine the risk factors for the first episode of bacterial pneumonia among human immunodeficiency virus (HIV)-seropositive injection drug users (IDUs), medical record review was performed on IDUs participating in a cohort study from January 1988 to June 30, 1992. HIV-seropositive IDUs with a first episode of bacterial pneumonia (n = 40) were matched with up to five HIV-seropositive control subjects without bacterial pneumonia (n = 197) by date of entry (+/- 3 mo) and length of follow-up. Odds ratios (OR) were estimated using conditional logistic regression. The incidence of bacterial pneumonia was 1.93 in 100 person-years in HIV seropositive and 0.45 in 100 person-years in HIV seronegative subjects (relative incidence = 4.3; 95% CI 2.4 to 7.5). In univariate analyses, CD4 lymphocyte count < 200 cells/microliters previous episode of Pneumocystis carinii pneumonia (PCP), age between 30 and 40 yr and smoking illicit drugs (marijuana, cocaine, or crack) were associated with bacterial pneumonia. Cigarette smoking was associated with an increased odds of bacterial pneumonia (OR = 2.0), but this was not statistically significant because it was nearly universal in this cohort. In multivariate analysis, CD4 < 200 cells/microliters (OR = 6.75, 95% CI 2.13 to 21.42) and smoking illicit drugs (OR = 2.24, 95% CI 1.03 to 4.89) remained significantly associated with bacterial pneumonia. The odds ratio for cigarette smoking in the final model remained at 2.08 but was still not significant (95% CI 0.49 to 8.70). Smoking illicit drugs had the strongest effect on risk of bacterial pneumonia among HIV-seropositive IDUs with a previous history of PCP (OR = 22.94; 95% CI 2.18 to 241.10).

This article has been cited by other articles:

				C. S. Restrepo, J. A. Carrillo, S. Martinez, P. Ojeda, A. L. Rivera, and A. Hatta Pulmonary Complications from Cocaine and Cocaine-based Substances: Imaging Manifestations RadioGraphics, July 1, 2007; 27(4): 941 - 956. [Abstract] [Full Text] [PDF]

				M. R. Irwin, L. Olmos, M. Wang, E. M. Valladares, S. J. Motivala, T. Fong, T. Newton, A. Butch, R. Olmstead, and S. W. Cole Cocaine Dependence and Acute Cocaine Induce Decreases of Monocyte Proinflammatory Cytokine Expression across the Diurnal Period: Autonomic Mechanisms J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 507 - 515. [Abstract] [Full Text] [PDF]

				M. D. Wewers, S. Lemeshow, A. Lehman, T. L. Clanton, and P. T. Diaz Lung CD4 Lymphocytes Predict Survival in Asymptomatic HIV Infection Chest, October 1, 2005; 128(4): 2262 - 2267. [Abstract] [Full Text] [PDF]

				A. Elssner, J. E. Carter, T. M. Yunger, and M. D. Wewers HIV-1 Infection Does Not Impair Human Alveolar Macrophage Phagocytic Function Unless Combined With Cigarette Smoking Chest, March 1, 2004; 125(3): 1071 - 1076. [Abstract] [Full Text] [PDF]

				J. H. Halpern, M. B. Sholar, J. Glowacki, N. K. Mello, J. H. Mendelson, and A. J. Siegel Diminished Interleukin-6 Response to Proinflammatory Challenge in Men and Women after Intravenous Cocaine Administration J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1188 - 1193. [Abstract] [Full Text] [PDF]

				T. A. Sarafian, S. Kouyoumjian, F. Khoshaghideh, D. P. Tashkin, and M. D. Roth Delta 9-Tetrahydrocannabinol disrupts mitochondrial function and cell energetics Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L298 - L306. [Abstract] [Full Text] [PDF]

				C. Mayaud, A. Parrot, and J. Cadranel Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients Eur. Respir. J., July 1, 2002; 20(36_suppl): 28S - 39s. [Abstract] [Full Text] [PDF]

				E. Cordero, E. Bouza, I. Ruiz, and J. Pachon Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial J. Antimicrob. Chemother., October 1, 2001; 48(4): 527 - 534. [Abstract] [Full Text] [PDF]

				J. H. SULLIVAN, R. D. MOORE, J. C. KERULY, and R. E. CHAISSON Effect of Antiretroviral Therapy on the Incidence of Bacterial Pneumonia in Patients with Advanced HIV Infection Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 64 - 67. [Abstract] [Full Text]

				D. Vlahov, N. Graham, D. Hoover, C. Flynn, J. G. Bartlett, J. B. Margolick, C. M. Lyles, K. E. Nelson, D. Smith, S. Holmberg, et al. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count JAMA, January 7, 1998; 279(1): 35 - 40. [Abstract] [Full Text] [PDF]

				R. L. DuPont, P. D. Kanof, W. A. Hensel, L. Domino, R. M. Dorizzi, A. Taub, M. E. Deutsch, D. Grant, J. E. Copple, J. A. Tilelli, et al. Medicinal Marijuana? N. Engl. J. Med., April 17, 1997; 336(16): 1184 - 1187. [Full Text]

				Bacterial Pneumonia and Smoking Illicit Drugs AIDS Clinical Care, February 1, 1995; 1995(201): 9 - 9. [Full Text]